Analyst Price Target is $36.50
▲ +27.67% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Lakefront Biotherapeutics American Depositary Shares in the last 3 months. The average price target is $36.50, with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 27.67% upside from the last price of $28.59.
Current Consensus is
Hold
The current consensus among 7 contributing investment analysts is to hold stock in Lakefront Biotherapeutics American Depositary Shares. This rating has held steady since February 2026, when it changed from a Reduce consensus rating.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Read More
